Jingtao Gao, PhD, deputy director of Managing Office of Clinical Center on TB, China CDC. She has been engaging in the field of TB prevention and control for 12 years. She attained her master degree on internal medicine from Peking Union Medical University in 2008. Then, she got her PhD on internal medicine from Beijing Tuberculosis and Thoracic Tumor Research Institute in 2015. She worked in Keio University in Japan as advanced visiting scholar 2013-2015 on respiratory research. Her special interests include TB clinical practice, programmatic management and research activities on drug resistant TB treatment. She is the key member of China TB Clinical Trial Consortium (CTCTC), and engaged in the planning, coordination and development on research activities of the consortium.In addition, she was involved for mentoring and supporting consortium investigators for research data management and manual writing.
In addition, she was involved for mentoring and supporting consortium investigators for research data management and manual writing. The practices and experiences accumulated from 10 more national level TB scientific studies or projects such as 11th-Five-Year National Science and Technology Major Project on drug resistance emergence mechanism and early warning model building sponsored by Ministry of Science and Technology of the People’s Republic of China (MOST) , followed by two 12th-Five-Year Projects on new treatment regimens for drug resistant TB and efficacy of ultra-short course chemotherapy for newly diagnosed smear positive drug susceptible TB. Moreover, she was designated as PI of the 13th- Five-Year Projects on exploring mechanism of TB recurrence after treatment success of MDR-TB patients and also served as the Co-PI of Regional Prospective Observational Research in Tuberculosis (RePORT) which is a multi-country cohort study. Recent 3 years, she was designated as the director of department of clinical trial of Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing) responsible for protocol design, EDC development, data management and research quality control in several phase III-IV clinical trials of the new anti-TB drugs.